'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Survival Gains In Third Line Patients

Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.

Gilead HQ
Gilead's $21bn acquisition of Immunomedics is set for completion by the end of 2020.

Immunomedics, Inc.’s Trodelvy (sacituzumab govitecan-hziy) has been hailed as a likely “new standard of care” thanks to impressive new overall survival data in third-line metastatic triple negative breast cancer (mTNBC).

The Phase III ASCENT study showed that the antibody-drug conjugate (ADC) doubled overall survival (OS) in heavily pre-treated patients compared...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category